Today the UK Department of Health and Social Care launched a new strategy to boost NHS access to innovative medical technology. Prof Phil Richardson shares his thoughts and reflections on the new policy.
Read More
Will NHS leaders, as part of an Integrated Care System (ICS), make conscious decisions to drive economic and social change? What social and economic value do ICSs offer the wider...
Read More
Katie Rose (Market Access Consultant) tells is about her experiences and activities in her first few weeks with us.
Working with a dedicated market access and health economics and outcomes research (HEOR) consultancy offers significant added value to Pharma and Medical Device companies and can give you the confidence...
Read More
The NHS Confederation has published a report exploring health economics in the NHS, with contributions from a range of leaders and innovators, including our own Prof Phil Richardson.
The proposed new NHS England (NHSE) systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects of policy...
Read More
With so many patients left waiting for NHS care, what will the long-term impact be? How can Pharma and Medtech support the NHS with systematic challenges, like waiting? Where can...
Read More
Prof Phil Richardson join Mtech Access as Chair and Chief Innovation Officer. His initial focus will be to bring together the NHS, industry and academia to drive innovation through partnership and collaboration.
On 29th September 2022, we brought together market access professionals from across Pharma and Medtech for our NHS Engagement Symposium: ‘People, pathways and payments – Mastering the key pillars of…
What do NHS customers value? What drives their decision-making? We asked our pool of NHS Associates – here are their responses.
